Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Biomarkers for Early Detection of Pancreatic Cancer

Bengtsson, Axel LU ; Andersson, Roland LU ; Linders, Johan LU ; Gulla, Aiste and Ansari, Daniel LU (2025) In Visceral Medicine 41(5). p.262-270
Abstract

Background: Pancreatic cancer continues to retain the highest mortality rate among all major organ cancers. New strategies for early detection are being proposed to increase long-term survival. A plethora of molecular markers are discovered yearly, but so far none have demonstrated screening utility. Summary: Promising discovery technologies include affinity-based proteomics and ddPCR. In the validation phase, researchers must decide on key benchmark criteria, what type of pancreatic lesions are desirable to find early through molecular screening, and when to terminate the biomarker study and return to the discovery phase. If the biomarkers meet set benchmarks, retrospective analysis should be conducted in relevant cohorts based on... (More)

Background: Pancreatic cancer continues to retain the highest mortality rate among all major organ cancers. New strategies for early detection are being proposed to increase long-term survival. A plethora of molecular markers are discovered yearly, but so far none have demonstrated screening utility. Summary: Promising discovery technologies include affinity-based proteomics and ddPCR. In the validation phase, researchers must decide on key benchmark criteria, what type of pancreatic lesions are desirable to find early through molecular screening, and when to terminate the biomarker study and return to the discovery phase. If the biomarkers meet set benchmarks, retrospective analysis should be conducted in relevant cohorts based on intended use, followed by prospective real-world evaluation. Lastly, regulatory approval, incorporation into clinical practice guidelines, and thorough health economic evaluations must be completed before the screening markers can be fully implemented. Key Messages: In this review, important strategies and phases for molecular biomarker development in pancreatic cancer have been outlined.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biomarkers, Early detection, Pancreatic cancer
in
Visceral Medicine
volume
41
issue
5
pages
262 - 270
publisher
Karger
external identifiers
  • scopus:105010155569
  • pmid:40612538
ISSN
2297-4725
DOI
10.1159/000546584
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2025 The Author(s).
id
062aebdc-841c-40f1-9c5c-b4d8d9fad1b0
date added to LUP
2025-12-19 13:45:51
date last changed
2025-12-20 03:00:15
@article{062aebdc-841c-40f1-9c5c-b4d8d9fad1b0,
  abstract     = {{<p>Background: Pancreatic cancer continues to retain the highest mortality rate among all major organ cancers. New strategies for early detection are being proposed to increase long-term survival. A plethora of molecular markers are discovered yearly, but so far none have demonstrated screening utility. Summary: Promising discovery technologies include affinity-based proteomics and ddPCR. In the validation phase, researchers must decide on key benchmark criteria, what type of pancreatic lesions are desirable to find early through molecular screening, and when to terminate the biomarker study and return to the discovery phase. If the biomarkers meet set benchmarks, retrospective analysis should be conducted in relevant cohorts based on intended use, followed by prospective real-world evaluation. Lastly, regulatory approval, incorporation into clinical practice guidelines, and thorough health economic evaluations must be completed before the screening markers can be fully implemented. Key Messages: In this review, important strategies and phases for molecular biomarker development in pancreatic cancer have been outlined.</p>}},
  author       = {{Bengtsson, Axel and Andersson, Roland and Linders, Johan and Gulla, Aiste and Ansari, Daniel}},
  issn         = {{2297-4725}},
  keywords     = {{Biomarkers; Early detection; Pancreatic cancer}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{262--270}},
  publisher    = {{Karger}},
  series       = {{Visceral Medicine}},
  title        = {{Biomarkers for Early Detection of Pancreatic Cancer}},
  url          = {{http://dx.doi.org/10.1159/000546584}},
  doi          = {{10.1159/000546584}},
  volume       = {{41}},
  year         = {{2025}},
}